Par j 2 IgE measurement for distinguishing between sensitization and allergy  by Comite, Paola et al.
lable at ScienceDirect
Allergology International 64 (2015) 384e385Contents lists avaiAllergology International
journal homepage: http : / /www.elsevier .com/locate/al i tLetter to the EditorPar j 2 IgE measurement for distinguishing between sensitization and
allergyDear Editor,
Allergic rhinitis is characterized by IgE-mediated allergic inﬂam-
mation consequent to the contact between IgE and allergen.1 IgE
maybe considered the hallmark of allergy, as IgE negativity excludes
the allergic causality. However, IgE positivity may mean both mere
sensitization and true allergy. Sensitization is documented by the
presence of allergen-speciﬁc IgE in the serum or by positive skin
prick test. Conversely, allergy is demonstrated by the correspon-
dence between proved sensitization and symptom occurrence after
exposure to the sensitizing allergen. Unfortunately, many people
consider a positive test as an evidence of allergy. Moreover, poly-
sensitization, such as sensitization to two or more allergens, is
very common: up to 80% of allergic patients.2 This phenomenon
has clinical implications mainly concerning allergen immuno-
therapy (AIT), as there are allergists who prefer to not prescribe
AIT in poly-sensitized patients. However, it has been demonstrated
that poly-sensitization should not be considered an obstacle for AIT,
as it is effective also in such patients.3 As a consequence, it is crucial
to distinguish sensitization from allergy, mainly in poly-sensitized
patients. For this purpose, a cause-effect link between IgE evidence
and clinical feature should be demonstrated, but it is not always
easy to differentiate sensitization from allergy: for example the
pollination periods of different pollen species may frequently over-
lap. Previously, it has been reported that serum allergen-speciﬁc IgE
measurement is better than skin prick test in managing poly-
sensitized patients.4 Serum IgE assessment is a standardized quan-
titative measurement that is commonly used in the allergy practice.
In addition, molecular-based allergy diagnostics allows to precisely
deﬁne and to characterize the sensitization proﬁle in order to deﬁne
AIT prescription.5 In fact, positivity tomajor allergens excludes false
reactivity to pan-allergens. Parietaria allergy is themost common in
our area. Par j 2 is a lipid transfer protein (LTP) that usually does not
cross-react with other LTP, such as Pru p 3. Par j 2 is the genuine and
major molecule of Parietaria judaica family allergens.6 Therefore,
Par j 2 positivity conﬁrms true sensitization to Parietaria.
This retrospective study aimed to evaluate whether the serum
IgE to Par j 2 assessment could differentiate between sensitization
and allergy in a group of 101 subjects (51 females, mean age 43
years) with serum IgE positivity only to Par j 2, such as
>0.35 kUA/L, and history of nasal symptoms, including itching,
sneezing, watery rhinorrhea, and nasal obstruction. The study
was performed according to the Review Board rules.Peer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).Patients were subdivided in two groups: sensitized subjects
(without symptoms after exposure to Parietaria pollen) and allergic
patients (with symptoms occurring after Parietaria pollen inhala-
tion). The Parietariapollen seasonusually has twoperiods: fromApril
till June and from September till October in our geographic area.
Serum levels of speciﬁc IgE were detected by the IFMA proce-
dure (ImmunoCAP Thermo Fisher Scientiﬁc, Uppsala, Sweden) in
peripheral blood samples from patients. Serum was collected into
gel-separator tubes, centrifuged and stored at 20 C until analysis
for Par j 2. Measurement of circulating speciﬁc IgE antibodies was
performed according to manufacturer's instructions.7 Speciﬁc Ig E
concentrations were expressed in kUA/L according to the traceable
calibration to the 2nd IRP WHO for Human IgE and 0.35 kUA/L has
been considered as a cut-off.8
Medians (md), and percentiles (25th and 75th, IQR) were used
as descriptive statistics. The non parametric Wilcoxon's test was
used to compare samples. In addition, a receiver operating charac-
teristic (ROC) curve analysis was performed in order to determine a
cut-off for sIgE that could optimize both the sensitivity and the
speciﬁcity of the test, for predicting the probability for true allergy,
such as symptoms occurrence after Parietaria pollen inhalation in
relation to speciﬁc immunoglobulin E (sIgE) levels. A p-value
0.05 was considered statistically signiﬁcant. All data were
analyzed using the Stata statistical package, Release 13.1 Statistical
Software. (StataCorp, College Station, TX, USA).
Fig. 1 shows the main ﬁndings. Firstly, 71 patients were allergic,
whereas 30 were only sensitized. Par j 2 IgE were signiﬁcantly
(p < 0.0001) higher in allergic patients (md 24.2 kUA/L;
IQR ¼ 16.1e61.2 kUA/L) than in sensitized subjects (md ¼ 2.9 kUA/
L; IQR¼ 1.4e5.9 kUA/L). ROCmethodology pointed out a high overall
accuracy for Par j 2 IgE (AUC¼ 0.93, 95% C.I.¼ 0.86e0.97). On the ba-
sis of Youden Index, a cut-off valuewas estimated:>6.52 kUA/L (sen-
sibility 100%, speciﬁcity 86.7%). The PPV was 94.7 and NPV 100.
The diagnosis of allergic rhinitis is based on the concordance be-
tween history of typical nasal symptoms and documented sensitiza-
tion, such as the demonstration of the consistency between the
exposure to sensitizing allergen and the resulting symptom occur-
rence.9,10 Sensitization may be documented by SPT and/or serum
IgE assay. However, there may be an overlapping concerning the
pollination period so it is difﬁcult to differentiate the most relevant
allergen on the basis of symptom period. Therefore, there is the need
to have the possibility of easily distinguish between sensitization
and allergy, mainly in particular context such as poly-sensitization
or presence of confounding factors (overlapped pollen seasons).
This study showed that more than 2/3 of considered subjects was
allergic to Parietaria pollens, so it conﬁrms the concept that notvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Upper left quadrant ¼ percentages of sensitized subjects and allergic patients to Par j 2. Upper right quadrant ¼ serum IgE to Par j 2 levels in sensitized subjects and allergic
patients. Lower left quadrant ¼ ROC curve to deﬁne cut-off level. Lower right quadrant ¼ distribution of IgE levels to deﬁne cut-off level.
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was a signiﬁcant difference of serum Par j 2 IgE levels between
allergic patients and sensitized subjects. The statistical analysis
deﬁned a reliable cut-off able to predict Parietaria allergy:
>6.52 kUA/L. Therefore, serum speciﬁc-IgE measurement might
signiﬁcantly improve the diagnostic capability of the clinician, even
though the main limitations of this study were that: it was cross-
sectional, we included only patients with mono-positivity IgE, thus
excluding patients with local allergic rhinitis and/or poly-
sensitization, we did not evaluated also Par j 1, the other major
component of Parietaria, as thismoleculewas not available in our lab.
However, these ﬁndings support the relevance of serum IgE
measurement as it is a precise and quantitativemethods to evaluate
IgE and may be useful in the allergy workup.
In conclusion, serum Par j 2 IgE measurement is a precise and
quantitative method to evaluate IgE, and may be useful in the al-
lergy workup, as could differentiate sensitization from allergy in
subjects sensitized to Parietaria pollen.
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